Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to
vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95 …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

During malignant transformation, glycosylation is heavily altered compared with healthy
tissue due to differential expression of glycosyltransferases, glycosidases and …

Chimeric antigen receptor (CAR) therapy targeting CD19 has yielded remarkable outcomes
in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute …

Midostaurin was recently approved by the US Food and Drug Administration for the
treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive …

Purpose To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …

Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis.
Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ …

Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of
gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves …

The concept of exploiting the specific binding properties of monoclonal antibodies as a
mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to …